Funded under Horizon Europe’s Innovative Health Initiative (HORIZON-JU-IHI-2022-02-01) and running from 2023 to 2028, the iCARE4CVD project aims to improve patient care across the board, starting from those at risk of developing cardiovascular disease to those with advanced heart failure. Thomas More University of Applied Sciences plays an important role in the project focusing data analysis and AI modeling as well as on the implementation of Patient-Reported Outcome Measures and Patient-Reported Experience Measures. Find out more in the full article.

Digitale Wolven, a Belgian non-profit organisation, forms the national hub for Belgium and the Netherlands in the Digital Europe project Code4Europe. Code4Europe aims to form a generation that is comfortable with digital tools and confident enough to build with them by widening digital literacy, making coding accessible to people who would otherwise never try it, and encouraging young people to picture themselves working in the digital sector.

The YoPA project, ‘a youth-centred preventive action approach towards co-created implementation of socially and physically activating environmental interventions’ obtained funding from Horizon Europe’s Health Cluster. The project addresses the multifaceted challenges of physical inactivity and health inequalities through a unique participatory approach. The project places teenagers between 12 and 18 years old in vulnerable situations at the forefront of the intervention process. The Institute of Tropical Medicine is a partner in the project and will conduct a Realist Evaluation to understand how youth co-creation contributes to improved adolescent health and well-being in four cities in Denmark, Netherlands, Nigeria and South Africa.  By integrating its results and sharing its approach in an open access Toolbox, ITM aims to contribute to fostering sustainable, youth-led solutions for healthier urban environments.

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.